Mitchell Davis Selected Research

Mitchell Davis Research Topics

3	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2022 - 01/2021
3	Fibrosis (Cirrhosis) 01/2017 - 01/2016
3	Chronic Hepatitis C 01/2017 - 04/2014
3	Infections 01/2017 - 04/2014
2	ST Elevation Myocardial Infarction 01/2022 - 11/2021
2	Hypertension (High Blood Pressure) 11/2021 - 01/2021
1	Tardive Dyskinesia 03/2024
1	Psoriasis (Pustulosis Palmaris et Plantaris) 10/2023
1	Sunburn 10/2023
1	Psoriatic Arthritis 10/2023
1	Wounds and Injuries (Trauma) 05/2023
1	Activated Protein C Resistance (APC Resistance) 01/2023
1	Death (Near-Death Experience) 01/2023
1	Myocardial Infarction 01/2023
1	Non-ST Elevated Myocardial Infarction 01/2022
1	Hyperlipidemias (Hyperlipidemia) 11/2021
1	Thrombocytopenia (Thrombopenia) 11/2021
1	Allergic Contact Dermatitis 01/2021
1	Fatigue 01/2017
1	Headache (Headaches) 01/2017
1	Nausea 01/2017
1	Diarrhea 01/2017

3	Inosine Triphosphate (ITP)IBA 01/2022 - 01/2021
3	SofosbuvirIBA 01/2017 - 01/2016
2	voxilaprevirIBA 01/2017 - 11/2016
2	velpatasvirIBA 01/2017 - 11/2016
2	Antiviral Agents (Antivirals)IBA 01/2017 - 11/2016
1	Pimozide (Orap)FDA Link 03/2024
1	guselkumabIBA 10/2023
1	Monoclonal AntibodiesIBA 10/2023
1	Codon (Codons)IBA 01/2023
1	APTIBA 01/2023
1	factor V LeidenIBA 01/2023
1	Petrolatum (Vaseline)FDA Link 01/2021
1	EmollientsIBA 01/2021
1	NucleotidesIBA 01/2017
1	sofosbuvir velpatasvir voxilaprevir drug combinationIBA 01/2017
1	SimeprevirIBA 01/2016
1	Ribavirin (Virazole)FDA LinkGeneric 04/2014
1	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 04/2014